logo

Tinea Pedis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Route of Administration (Oral, Topical) Distribution Channel and by Geography

Home Industry Reports Healthcare Tinea Pedis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2 ...

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The tinea pedis treatment market studied was projected to grow with a CAGR of 4.8% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of fungal infections. Mycotic diseases are global in distribution, but maximum cases are recorded from tropical and subtropical countries. As the number of patients increases the market growth also rises. Furthermore, the increasing research and development programs and funding for the same is boosting the market growth. However, lack of awareness of the treatment and stringent approval regulations constraints the market growth.

Scope of the Report

As per the scope of the report tinea pedis (Athlete's foot) is a fungal infection that usually begins between the toes. It commonly arises in people whose feet have become very sweaty while restricted within tightfitting shoes. This report is segmented by Route of Administration, Distribution Channel and by Geography.

By Route of Administration
Oral
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Topical Segment is Dominating the Tinea Pedis Treatment Market

  • The major share of the segment is attributed to the increasing number of fungal infections and the advantages of the topical route of administration over oral. These include a low risk of systemic adverse events and drug interactions, low cost, smaller amounts of drug is used, etc.
  • According to the Journal of Applied Microbiology and Biochemistry of 2017, globally, 800 million people in the world have suffered from one or other types of fungal diseases.
  • The large patient pool and increasing research and development programs and funding are propelling the segment growth.
Fungal

North America Dominates the Market and Expected to do Same in the Forecast Period

  • North America is expected to dominate the overall market, throughout the forecast period. this is mainly due to the factors such as the presence of key players, well-established healthcare infrastructure are some of the key factors accountable for its large share in the market.
  • Furthermore, beneficial government initiatives are expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market.
Tinea Pedis Treatment Market - Growth Rate by Region

Competitive Landscape

The Tinea Pedis Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are GlaxoSmithKline, Bausch Health, Glenmark Pharmaceuticals, Bayer AG, Sanofi, Sun Pharma, Teva Pharmaceutical, Celgene.

Tinea Pedis Treatment Market.png

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Huge Number of People With Fungal Infection

      2. 4.2.2 Increasing Research and Development Activities

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness of Effective Treatment

      2. 4.3.2 Stringent Approval Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Oral

      2. 5.1.2 Topical

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 E-Commerce

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline

      2. 6.1.2 Bausch Health

      3. 6.1.3 Glenmark Pharmaceuticals

      4. 6.1.4 Bayer AG

      5. 6.1.5 Sun Pharma

      6. 6.1.6 Sanofi

      7. 6.1.7 Teva Pharmaceutical

      8. 6.1.8 Celgene

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Tinea Pedis Treatment Market market is studied from 2018 - 2026.

The Tinea Pedis Treatment Market is growing at a CAGR of 4.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

GlaxoSmithKline, Glenmark Pharmaceuticals, Bayer AG, Bausch Health, Sun Pharma are the major companies operating in Tinea Pedis Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!